| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21ClN2OS |
| Molecular Weight | 360.901 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCC(=O)N1C2=CC(Cl)=CC=C2SC3=C1C=CC=C3
InChI
InChIKey=ZZKWNLZUYAGVOT-UHFFFAOYSA-N
InChI=1S/C19H21ClN2OS/c1-3-21(4-2)12-11-19(23)22-15-7-5-6-8-17(15)24-18-10-9-14(20)13-16(18)22/h5-10,13H,3-4,11-12H2,1-2H3
| Molecular Formula | C19H21ClN2OS |
| Molecular Weight | 360.901 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Chloracyzine is phenothiazine derivative with vasodilatory activity. Chloracyzine produced a decrease in myocardial oxygen consumption accompanied by a reduction in coronary blood flow preceded by transient coronary dilatation. Chloracyzine produced an insignificant increase in arterial pressure; heart rate increased slightly in the open-chest experiments but not in the isolated heart. It is suggested that reduced oxygen uptake after chloracyzine is realized through improved efficiency in the use of oxygen.
Originator
Approval Year
PubMed
Patents
|
|
SALT/SOLVATE -> PARENT |
Showing 1 to 1 of 1 entries
